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1865meta-analysis of 27 trials, all performed in the pre-
reperfusion era. Any comparison of the side effect
proﬁle between patients with STEMI not reperfused
by any means and those undergoing early primary
angioplasty is futile. Conversely, we agree with Dr.
Opie that the results of the COMMIT (Clopidogrel and
Metoprolol in Myocardial Infarction Trial) (3) should
be placed in perspective. We commented extensively
on the COMMIT results in our 2 previous publications,
and we refer the readers to the original publications
(1,2). To summarize, the side effects in the COMMIT
study were concentrated in patients at the highest risk
for shock: Killip class III and/or systolic hypotension
on presentation.We learned lessons from the COMMIT
study, and in the METOCARD-CNIC trial, patients
presenting with Killip class III and/or systolic blood
pressure below 120 mm Hg were contraindicated for
enrollment. Altogether, the COMMIT andMETOCARD-
CNIC trials suggest that a comprehensive selection of
patients for early IVmetoprolol treatmentmight result
in a signiﬁcant beneﬁt, with no increase in the fre-
quency of side effects. The ongoing EARLY-BAMI
(Early Beta-Blocker Administration Before Primary
PCI in Patients With ST-Elevation Myocardial Infarc-
tion) trial (Zwolle, the Netherlands) should conﬁrm the
infarct size reduction and increased long-term ven-
tricular function observed in the METOCARD-CNIC
trial. Even if conﬁrmed, infarct size and ventricular
function are surrogate markers, and a large random-
ized clinical trial with hard clinical endpoints should
be performed. The MOVE ON! (Impact of Pre-Reper-
fusion Metoprolol on Clinical Events After Myocardial
Infarction) trial will recruit more than 3,500 patients
with STEMI in 8 European countries, randomize them
to IV metoprolol or placebo during transfer to primary
angioplasty, and quantify the incidence of death or
heart failure admission over a median follow-up of 3
years. This trial will answer whether early IV meto-
prolol is the ﬁrst therapy used in conjunction with
primary angioplasty to improve clinical outcomes (4).*Borja Ibanez, MD, PhD
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Auscultatory Biomarker
or Imaging Biomarker?We read with interest the paper by Coffey et al.
(1) reporting the results of a meta-analysis on the
prevalence, incidence, and risks of aortic valve scle-
rosis (ASc). In this review, the authors demonstrated
that ASc is common in the general population and
is independently associated with an increased fre-
quency of major adverse cardiovascular and cere-
brovascular events (MACCE), as well as all-cause
mortality, making it a powerful “imaging biomarker.”
The researchers analyzed studies that deﬁned
ASc as any thickening or calciﬁcation of the aortic
valve—detectable by any means, such as transthoracic
or transesophageal echocardiogram or computed
tomography—without any signiﬁcant hemodynamic
effect. Although not directly addressing the results of
this meta-analysis, we want to take this opportunity
to address that mindful auscultation can lead one
in the right direction hours, days, and even weeks
before the same results can be achieved by those
who rely solely on modern technology.
We have a wonderfully rich tradition of physical
diagnostic signs in cardiology. However, in contem-
porary medicine, many have come to rely solely on
clinical imaging and laboratory testing, looking at
physical diagnostic signs askance and thus neglecting
or even discarding knowledge acquired during
clinical training. Disregard for physical diagnostic
methods now pervades clinical training in the United
States, and the art of physical diagnosis has been
reduced to a mere vestige, with several experts con-
tending that physical diagnosis has little to offer the
modern clinician. This is particularly true of the
stethoscope, which some believe should be exiled to
the archives of medical history.
Without distracting the readers from the results
of this meta-analysis (1), it is important to note
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pre-revolutionary times of medicine (the revolution
in academic medicine having occulted in 1968
when the intellectual approach to diagnosis and
clinical examination fell into disrespect) (2), using
onomatopoeia, clinicians have learned the cadence
of heart murmurs, which sometimes led to rapid
recognition of valvular pathology. The murmur of
ASc resembles that of mild calciﬁc aortic valve ste-
nosis (CAVS). It is soft, early systolic, loudest in the
aortic area (right second intercostal space), with
radiation toward the base of the neck. It contains
both high- and low-frequency components that
sometimes result in a harsh or rough sound. How-
ever, other customary ﬁndings of CAVS (“pulsus
parvus et tardus,” sustained apical impulse, reduced
intensity of the second heart sound, and mid- to
late-peaking murmur) are absent.
According to the latest American College of Cardi-
ology and American Heart Association guidelines for
valvular heart disease (3), ASc (classiﬁed as “stage A”
valvular aortic stenosis) is deﬁned on Doppler echo-
cardiographic measurement with maximum trans-
valvular velocity (Vmax) of <2 m/s. In our experience,
we have clearly auscultated murmurs of ASc with
varying Vmax (1.4 to 2.0 m/s). It is our experience
that auscultation, although poor at differentiating
moderate from severe CAVS, is very reliable at
detecting ASc or mild CAVS, which is later conﬁrmed
by imaging.
This meta-analysis (1) combined the results of a
select group of studies (introducing selection bias)
wherein ASc was diagnosed by cardiac imaging. This
begs the question of “missed” diagnoses of ASc in the
real-world setting, wherein individual bias of physi-
cians prevails when they continue to argue that echo-
cardiography should not be ordered for “innocent”
systolic murmurs in patients who are asymptomatic
and have otherwise normal ﬁndings on examination,
for the sake of realizing cost savings. It is quite clear
from the study of Coffey et al. (1) that ASc is a marker of
general vascular disease, with an attendant increase in
the frequency of all reported MACCE types. Indeed, by
its very deﬁnition, ASc is asymptomatic and without
any detectable hemodynamic effects, and yet it carriesclinical importance of high magnitude. Thus, its early
recognition by the stethoscope and conﬁrmation by
cardiac imaging will aid in patient satisfaction and
downstream cost savings. Because the trials aimed
at slowing the progression of established CAVS have
been negative—the proverbial “horse is out of the
barn”—detection of disease in its incipient state is
required to permit more effective preventive in-
terventions. Hence, detection of ASc by auscultation
is of great importance, and the value of this bedside
“auscultatory biomarker” is evident, die method ist
alles.
In summary, we would like to emphasize that it is
perilous to tread the path of extreme polar views
wherein the warriors of physical examination (rep-
resented primarily by the stethoscope in cardiology)
believe that traditional physical signs remain accu-
rate today, whereas its adversaries advocate a
coup de grace for it. Neither position, of course, is
completely correct. However, we must continue to
embrace modern technology because it complements
rather than replaces that unique tradition of physical
examination. A well-executed examination is at
the heart of the physician-patient interaction—the
art of medicine—and provides critical information
necessary to choose the right diagnostic imaging—the
science of medicine.M. Fuad Jan, MBBS, MD
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